{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": false, "customPriceAlertConfidence": "LOW", "currency": "EUR", "exchange": "FRA", "shortName": "MERUS N.V.  EO -,09", "longName": "Merus N.V.", "messageBoardId": "finmb_24929296", "exchangeTimezoneName": "Europe/Berlin", "exchangeTimezoneShortName": "CEST", "gmtOffSetMilliseconds": 7200000, "market": "dr_market", "esgPopulated": false, "fullExchangeName": "Frankfurt", "financialCurrency": "USD", "regularMarketOpen": 18.8, "averageDailyVolume3Month": 10, "averageDailyVolume10Day": 0, "fiftyTwoWeekLowChange": 6.8999996, "fiftyTwoWeekLowChangePercent": 0.5798319, "fiftyTwoWeekRange": "11.9 - 28.0", "fiftyTwoWeekHighChange": -9.200001, "fiftyTwoWeekHighChangePercent": -0.32857147, "fiftyTwoWeekLow": 11.9, "fiftyTwoWeekHigh": 28.0, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "epsTrailingTwelveMonths": -2.87, "epsForward": -2.94, "epsCurrentYear": -2.34, "priceEpsCurrentYear": -8.034188, "sharesOutstanding": 46530900, "bookValue": 5.335, "fiftyDayAverage": 17.606, "fiftyDayAverageChange": 1.1939983, "fiftyDayAverageChangePercent": 0.06781769, "twoHundredDayAverage": 18.09, "twoHundredDayAverageChange": 0.7099991, "twoHundredDayAverageChangePercent": 0.039248154, "marketCap": 907032256, "forwardPE": -6.3945575, "priceToBook": 3.5238986, "sourceInterval": 15, "exchangeDataDelayedBy": 15, "averageAnalystRating": "1.5 - Strong Buy", "tradeable": false, "cryptoTradeable": false, "regularMarketChangePercent": 0.5347512, "regularMarketPrice": 18.8, "marketState": "REGULAR", "firstTradeDateMilliseconds": 1525672800000, "priceHint": 2, "regularMarketChange": 0.099998474, "regularMarketTime": 1683875702, "regularMarketDayHigh": 18.8, "regularMarketDayRange": "18.8 - 18.8", "regularMarketDayLow": 18.8, "regularMarketVolume": 300, "regularMarketPreviousClose": 18.7, "bid": 18.4, "ask": 19.1, "bidSize": 0, "askSize": 0, "symbol": "2GH.F"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "Uppsalalaan 17", "address2": "3rd & 4th floor", "city": "Utrecht", "zip": "3584 CT", "country": "Netherlands", "phone": "31 30 253 8800", "website": "https://www.merus.nl", "industry": "Biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; and collaboration with Incyte Corporation for the development of MCLA-145. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.", "fullTimeEmployees": 164, "companyOfficers": [{"maxAge": 1, "name": "Dr. Sven Ante Lundberg M.D.", "age": 59, "title": "CEO, Pres, Principal Financial Officer & Exec. Director", "yearBorn": 1963, "fiscalYear": 2022, "totalPay": {"raw": 953062, "fmt": "953.06k", "longFmt": "953,062"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 453280, "fmt": "453.28k", "longFmt": "453,280"}}, {"maxAge": 1, "name": "Mr. Peter B. Silverman J.D.", "age": 44, "title": "EVP, Company Sec., COO, Gen. Counsel, Chief Intellectual Property Officer & Head of US Legal", "yearBorn": 1978, "fiscalYear": 2022, "totalPay": {"raw": 601187, "fmt": "601.19k", "longFmt": "601,187"}, "exercisedValue": {"raw": 947400, "fmt": "947.4k", "longFmt": "947,400"}, "unexercisedValue": {"raw": 129054, "fmt": "129.05k", "longFmt": "129,054"}}, {"maxAge": 1, "name": "Dr. Hui  Liu Ph.D.", "age": 55, "title": "Chief Bus. Officer, Exec. VP & Head of Merus U.S.", "yearBorn": 1967, "fiscalYear": 2022, "totalPay": {"raw": 597700, "fmt": "597.7k", "longFmt": "597,700"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 1032039, "fmt": "1.03M", "longFmt": "1,032,039"}}, {"maxAge": 1, "name": "Dr. Andrew  Joe M.D.", "age": 56, "title": "Chief Medical Officer & Sr. VP", "yearBorn": 1966, "fiscalYear": 2022, "totalPay": {"raw": 692739, "fmt": "692.74k", "longFmt": "692,739"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 109897, "fmt": "109.9k", "longFmt": "109,897"}}, {"maxAge": 1, "name": "Dr. Hennie  Hoogenboom", "title": "Co-Founder and Scientific Advisor", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Harry  Shuman", "title": "Chief Accounting Officer", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Cornelis Adriaan de Kruif Ph.D.", "age": 57, "title": "CTO & Exec. VP", "yearBorn": 1965, "fiscalYear": 2018, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Cecilia Anna Wilhelmina Geuijen Ph.D.", "title": "Chief Scientific Officer & Sr. VP", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Jillian  Connell", "title": "VP of Investor Relations & Corp. Communications", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Alexander Berthold Hendrik Bakker Ph.D.", "age": 55, "title": "Chief Devel. Officer & Exec. VP", "yearBorn": 1967, "fiscalYear": 2018, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "compensationAsOfEpochDate": 1672444800, "maxAge": 86400}}], "error": null}}